Loading...
Docoh

Viatris (VTRS)

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India.

Company profile

Ticker
VTRS, 0A5V
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Former names
Upjohn Inc
SEC CIK
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Upjohn Australia Pty Ltd • Viatris Pty. Ltd. • Arcana Arzneimittel GmbH • Mylan Österreich GmbH • Viatris LLC • Meda Pharma N.V. ...
IRS number
834364296

VTRS stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$12.50
Low target
$9.00
High target
$16.00
BMO Capital
Maintains
Outperform
$16.00
9 Aug 22
UBS
Initiated
Sell
$9.00
14 Jun 22

Calendar

8 Aug 22
20 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 669.4M 669.4M 669.4M 669.4M 669.4M 669.4M
Cash burn (monthly) 29.33M 808.33K (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 49.39M 1.36M n/a n/a n/a n/a
Cash remaining 620.01M 668.04M n/a n/a n/a n/a
Runway (months of cash) 21.1 826.4 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Aug 22 der Meer Mohr Pauline van Common Stock Sell Dispose S No No 10.5839 9,440 99.91K 20,543
27 May 22 Menassie Taddese Common Stock Sell Dispose S No No 12.0737 8,813 106.41K 0
29 Mar 22 Xiangyang (Sean) Ni Common Stock Option exercise Acquire M No No 0 102 0 10,321
29 Mar 22 Xiangyang (Sean) Ni Common Stock Option exercise Acquire M No No 0 2,852 0 10,219
29 Mar 22 Xiangyang (Sean) Ni Dividend Equivalent Units Common Stock Option exercise Dispose M No No 0 101.855 0 0
29 Mar 22 Xiangyang (Sean) Ni RSU Common Stock Option exercise Dispose M No No 0 2,852 0 0
21 Mar 22 Menassie Taddese Common Stock Payment of exercise Dispose F No No 10.39 34 353.26 8,813
21 Mar 22 Menassie Taddese Common Stock Option exercise Acquire M No No 0 80 0 8,847
21 Mar 22 Menassie Taddese Dividend Equivalent Units Common Stock Grant Acquire A No No 0 253.245 0 592.245
21 Mar 22 Menassie Taddese Dividend Equivalent Units Common Stock Grant Acquire A No No 0 352.592 0 1,065.148
13F holders Current Prev Q Change
Total holders 943 979 -3.7%
Opened positions 89 99 -10.1%
Closed positions 125 148 -15.5%
Increased positions 302 314 -3.8%
Reduced positions 389 396 -1.8%
13F shares Current Prev Q Change
Total value 9.72B 9.93B -2.1%
Total shares 876.03M 877.85M -0.2%
Total puts 5.99M 7.25M -17.4%
Total calls 6.92M 7.69M -10.0%
Total put/call ratio 0.9 0.9 -8.3%
Largest owners Shares Value Change
Vanguard 145.34M $1.52B +5.1%
BLK Blackrock 93.51M $979.06M +5.9%
STT State Street 58.08M $608.14M +2.6%
Davis Selected Advisers 55.47M $580.73M -2.1%
Wellington Management 55.23M $578.29M 0.0%
Geode Capital Management 24.88M $260.05M +1.7%
Camber Capital Management 23M $240.81M 0.0%
Deerfield Management 20.67M $216.45M 0.0%
Laurion Capital Management 18.42M $192.87M -37.3%
Schroder Investment Management 16.53M $173.06M +1.4%
Largest transactions Shares Bought/sold Change
MCQEF Macquarie 3.22M -21.96M -87.2%
Laurion Capital Management 18.42M -10.97M -37.3%
Arrowstreet Capital, Limited Partnership 12.47M +9.13M +273.6%
LGEN Legal & General 0 -8.38M EXIT
Marshall Wace 392.91K -7.7M -95.1%
Vanguard 145.34M +6.99M +5.1%
Aqr Capital Management 10.1M +6.2M +159.0%
FHI Federated Hermes 6.02M +6M +25948.6%
Armistice Capital 500K -5.3M -91.4%
BLK Blackrock 93.51M +5.24M +5.9%

Financial report summary

?
Risks
  • We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
  • Increasing scrutiny and evolving expectations from customers, regulators, investors, employees, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
  • There can be no guarantee that we will continue to pay dividends or that we will implement repurchases under our stock buyback program.
  • If the intercompany terms of cross border arrangements that we have among our subsidiaries are determined to be inappropriate or ineffective, our tax liability may increase.
  • We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders.
  • Unanticipated changes in our tax provisions or exposure to additional income tax liabilities and changes in income tax laws and tax rulings may have a significant adverse impact on our effective tax rate and income tax expense.
  • Currency fluctuations and changes in exchange rates could adversely affect our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
  • There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.
  • We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis.
  • Viatris could suffer additional losses due to asset impairment charges.
  • Viatris may be adversely affected by disruptions in the credit markets, including disruptions that reduce customers’ access to credit and increase the costs to customers of obtaining credit.
  • In connection with the Combination, Viatris assumed or retained certain material obligations relating to defined benefit pension and termination benefits and retiree medical and dental benefits associated with legacy employees of the Upjohn Business and/or sponsored by Upjohn entities. These liabilities and the related future funding obligations could restrict cash available for Viatris’ operations, capital expenditures, dividend payments and other requirements, and may materially adversely affect Viatris’ financial condition and liquidity.
  • The market price of our common stock may be volatile, and the value of your investment could materially decline.
  • The expansion of social media platforms presents new risks and challenges.
  • Provisions in the Viatris Charter and Viatris Bylaws and of applicable law may prevent or delay an acquisition of Viatris, which could decrease the trading price of Viatris common stock.
  • The Viatris Charter designates the Court of Chancery of the State of Delaware, or, if such court lacks subject matter jurisdiction, another state court of the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware), as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by Viatris’ stockholders, which could discourage lawsuits against Viatris and its directors and officers.
Management Discussion
  • (1)Currency impact is shown as unfavorable (favorable).
  • (2)The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2022 constant currency net sales or revenues to the corresponding amount in the prior year.
  • (3)For the three months ended June 30, 2022, other revenues in Developed Markets and Emerging Markets were approximately $4.8 million and $6.6 million, respectively.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: coordinated, erosion, flat
Removed: begin, consuming, costly, implementation, integrate, lesser, principle, Recent, successfully